LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Market for IHC Tests Growing in Europe

By Labmedica staff writers
Posted on 31 Mar 2006
Immunohistochemistry (IHC) is emerging as an important tool for cancer diagnostics in Europe, following the development of new-generation diagnostic kits that can detect cancer at its earliest stages, according to a new report from Frost & Sullivan (Palo Alto, CA, USA), an international consulting firm.

Recent campaigns in Europe that improved patient management by encouraging people to test themselves for certain subtypes of cancer indicate that the focus of IHC diagnostics should be on early detection and treatment. Market revenues for IHC diagnostics are forecast to increase to U.S.$48.1 million by 2011 at an estimated compound annual growth rate of 4.7%.

"Timely disease detection offers compelling advantages such as reduced need for expensive therapies” said Frost & Sullivan research analyst Dr. Fiona Rahman. "This in turn brings down bed occupancy rates and reduces the burden on the healthcare system, driving governments to implement national cancer-screening programs across Europe.”

The IHC diagnostics market in Europe is highly competitive and manufacturers need to train company personnel who can educate end users on their products. Conferences or focus groups are being organized that provide a platform for clinicians, laboratory technicians, administrators, and product specialists to interact with each other and to become familiar with the latest practices and techniques in IHC testing.

The cost of IHC tests is higher than that of traditional testing methods. Dr. Rahman observes that companies will need to improve the automation of these tests radically to be competitive with more conventional technologies. "While physicians are reluctant to experiment with expensive IHC products, they are nevertheless essential to complement more traditional diagnostic methods” said Dr. Rahman. "The challenge for manufacturers, therefore, is to offer IHC products at cost-effective prices to encourage end users to experiment and successfully adopt these tests as routine diagnosis”


Related Links:
Frost and Sullivan
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
8-Channel Pipette
SAPPHIRE 20–300 µL

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more